Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Using EGFR amplification to stratify recurrent glioblastoma treated with immune checkpoint inhibitors
Authors
Keywords
-
Journal
CANCER IMMUNOLOGY IMMUNOTHERAPY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2023-01-28
DOI
10.1007/s00262-023-03381-y
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Topographic mapping of the glioblastoma proteome reveals a triple-axis model of intra-tumoral heterogeneity
- (2022) K. H. Brian Lam et al. Nature Communications
- mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers
- (2022) Lei Cheng et al. Journal of Translational Medicine
- Comprehensive Analysis Identifies PI3K/Akt Pathway Alternations as an Immune-Related Prognostic Biomarker in Colon Adenocarcinoma Patients Receiving Immune Checkpoint Inhibitor Treatment
- (2022) Anqi Lin et al. Journal of Immunology Research
- KRAS ‐G12D mutation drives immune suppression and the primary resistance of anti‐PD‐1/PD‐L1 immunotherapy in non‐small cell lung cancer
- (2022) Chengming Liu et al. Cancer Communications
- Treatment with pembrolizumab in programmed death ligand 1–positive recurrent glioblastoma: Results from the multicohort phase 1 KEYNOTE‐028 trial
- (2021) David A. Reardon et al. CANCER
- Analysis of the EGFR Amplification and CDKN2A Deletion Regulated Transcriptomic Signatures Reveals the Prognostic Significance of SPATS2L in Patients With Glioma
- (2021) Haiwei Wang et al. Frontiers in Oncology
- Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).
- (2021) Manmeet Singh Ahluwalia et al. JOURNAL OF CLINICAL ONCOLOGY
- The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
- (2021) David N Louis et al. NEURO-ONCOLOGY
- Emerging Role of EGFR Mutations in Creating an Immune Suppressive Tumour Microenvironment
- (2021) Simran S. Kapoor et al. Biomedicines
- Multiparametric MRI for early identification of therapeutic response in recurrent glioblastoma treated with immune checkpoint inhibitors
- (2020) Joseph Song et al. NEURO-ONCOLOGY
- Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma
- (2020) David A. Reardon et al. JAMA Oncology
- Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment
- (2020) Anaelle A Dumas et al. EMBO JOURNAL
- Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma
- (2020) Lakshmi Nayak et al. CLINICAL CANCER RESEARCH
- Tumor mutational load predicts survival after immunotherapy across multiple cancer types
- (2019) Robert M. Samstein et al. NATURE GENETICS
- Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma
- (2019) Junfei Zhao et al. NATURE MEDICINE
- Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
- (2019) Timothy F. Cloughesy et al. NATURE MEDICINE
- Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
- (2019) Antonio Santaniello et al. Cancers
- Retrospective study of nivolumab for patients with recurrent high grade gliomas
- (2018) Megan Mantica et al. JOURNAL OF NEURO-ONCOLOGY
- Prognostic significance of epidermal growth factor receptor expression in glioma patients
- (2018) Junhong Li et al. OncoTargets and Therapy
- Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
- (2018) Carl Morrison et al. Journal for ImmunoTherapy of Cancer
- PD-1 inhibition has only limited clinical benefit in patients with recurrent high-grade glioma
- (2018) Sylvia C. Kurz et al. NEUROLOGY
- Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series
- (2017) Marc C. Chamberlain et al. JOURNAL OF NEURO-ONCOLOGY
- Checkpoint Inhibitors in Metastatic EGFR- Mutated Non–Small Cell Lung Cancer—A Meta-Analysis
- (2017) Chee Khoon Lee et al. Journal of Thoracic Oncology
- Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143
- (2017) Antonio Omuro et al. NEURO-ONCOLOGY
- Lomustine and Bevacizumab in Progressive Glioblastoma
- (2017) Wolfgang Wick et al. NEW ENGLAND JOURNAL OF MEDICINE
- EGFR mutation correlates with uninflamed phenotype and weak immunogenicity, causing impaired response to PD-1 blockade in non-small cell lung cancer
- (2017) Zhong-Yi Dong et al. OncoImmunology
- Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas
- (2017) Samantha N. Reiss et al. Journal for ImmunoTherapy of Cancer
- EGFR Mutations and ALK Rearrangements Are Associated with Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis
- (2016) J. F. Gainor et al. CLINICAL CANCER RESEARCH
- Immune Checkpoint Inhibition for Hypermutant Glioblastoma Multiforme Resulting From Germline Biallelic Mismatch Repair Deficiency
- (2016) Eric Bouffet et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Somatic Genomic Landscape of Glioblastoma
- (2013) Cameron W. Brennan et al. CELL
- Targeting Ras-RAF-ERK and its Interactive Pathways as a Novel Therapy for Malignant Gliomas
- (2010) H.-W. Lo CURRENT CANCER DRUG TARGETS
- Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
- (2009) Henry S. Friedman et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search